

Resource Summary Report

Generated by [PRECISE-TBI](#) on Sep 8, 2026

Scalpel

RRID:SCR_012107

Type: Tool

Proper Citation

Scalpel (RRID:SCR_012107)

Resource Information

URL: <http://scalpel.sourceforge.net/>

Proper Citation: Scalpel (RRID:SCR_012107)

Description: A software package for detecting INDELs (INsertions and DEletions) mutations in a reference genome which has been sequenced with next-generation sequencing technology (e.g., Illumina).

Resource Type: software resource

Defining Citation: [PMID:25128977](#)

Keywords: software package, c++, perl, bio.tools

Resource Name: Scalpel

Resource ID: SCR_012107

Alternate IDs: biotools:scalpel, OMICS_05395

Alternate URLs: <https://bio.tools/scalpel>

Record Creation Time: 20220129T080308+0000

Record Last Update: 20260905T132720+0000

Ratings and Alerts

No rating or validation information has been found for Scalpel.

No alerts have been found for Scalpel.

Data and Source Information

Usage and Citation Metrics

We found 62 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Wei Y, et al. (2025) Efficient glycosylase-mediated base editing with minimal off-target effects in mammalian embryos. *Genome biology*, 26(1), 360.

Fu Y, et al. (2025) Integrated circulating tumor DNA-based prognostic algorithm for limited stage small-cell lung cancer under definitive chemoradiotherapy and utility in consolidation immunotherapy benefit prediction. *Cell communication and signaling : CCS*, 23(1), 480.

Ake F, et al. (2025) Quantification of transcript isoforms at the single-cell level using SCALPEL. *Nature communications*, 16(1), 6402.

Baluszek S, et al. (2025) TP53 mutations as drivers of chordoma progression and hallmarks of aggressive chordoma. *Acta neuropathologica communications*, 14(1), 24.

Zhang Y, et al. (2024) Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL). *Cell reports. Medicine*, 5(12), 101833.

Guille A, et al. (2024) A benchmarking study of individual somatic variant callers and voting-based ensembles for whole-exome sequencing. *Briefings in bioinformatics*, 26(1).

Xie L, et al. (2024) Undetectable off-target effects induced by FokI catalytic domain in mouse embryos. *Genome biology*, 25(1), 51.

Hobor S, et al. (2024) Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. *Nature communications*, 15(1), 4871.

Zhou F, et al. (2024) Clinicopathological and molecular features of lung cancers associated with cystic airspaces: an analysis of 34 cases. *Journal of thoracic disease*, 16(12), 8309.

Malamon JS, et al. (2024) A comparative study of structural variant calling in WGS from Alzheimer's disease families. *Life science alliance*, 7(5).

Hariprakash JM, et al. (2024) Leveraging Tissue-Specific Enhancer-Target Gene Regulatory Networks Identifies Enhancer Somatic Mutations That Functionally Impact Lung Cancer. *Cancer research*, 84(1), 133.

Elhassan YS, et al. (2024) Primary unilateral macronodular adrenal hyperplasia with concomitant glucocorticoid and androgen excess and KDM1A inactivation. *European journal of endocrinology*, 191(3), 334.

Caswell DR, et al. (2024) The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. *Nature genetics*, 56(1), 60.

Feng J, et al. (2023) Primary papillary epithelial tumor of the sella and posterior pituitary tumor show similar (epi)genetic features and constitute a single neuro-oncological entity. *Neuro-oncology*, 25(8), 1487.

Spain L, et al. (2023) Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways. *Cancer discovery*, 13(6), 1364.

Wei Y, et al. (2023) Human 8-cell embryos enable efficient induction of disease-preventive mutations without off-target effect by cytosine base editor. *Protein & cell*, 14(6), 416.

Valero C, et al. (2023) Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma. *The Journal of clinical investigation*, 133(19).

Wobser M, et al. (2022) Panel Sequencing of Primary Cutaneous B-Cell Lymphoma. *Cancers*, 14(21).

Li Y, et al. (2022) Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer. *Journal of oncology*, 2022, 1763778.

Au L, et al. (2021) Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. *Cancer cell*, 39(11), 1497.